Pharmacological evaluation of Glyco-Flex® III and its constituents on canine chondrocytes

Journal of Medical Sciences

Volumn 8, Issue 1, 2008, Pages 1-14

  Yćñez, Jaime A ^a   Remsberg, Connie M ^a   Vega Villa, Karina R ^a   Miranda, Nicole D ^b   Navas, Jinna ^a   Ohgami, Yusuke ^a   McCormick, David ^a   Hughes, Kelly ^a   Temple, Cara ^a   Martinez, Steven A ^a   Davies, Neal M ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CONCEPCIÓN   (Chile)

Author keywords

Anti oxidant; Chondrocytes; Cytokine; Glyco Flex III; Inflammation

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; COLLAGEN; DERACOXIB; DIMETHYL SULFONE; DIMETHYLGLYCINE; GLUCOSAMINE; GLYCO FLEX III; GLYCOSAMINOGLYCAN POLYSULFATE; GRAPE SEED EXTRACT; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITRATE; NITRIC OXIDE; NITRITE; PERNA CANALICULUS EXTRACT; PROSTAGLANDIN E2; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CARTILAGE CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG POTENCY; IN VITRO STUDY; NONHUMAN; PROTEIN DEGRADATION; TABLET;

EID: 42149182353     PISSN: 16824474     EISSN: 18125727     Source Type: Journal    
DOI: 10.3923/jms.2008.1.14     Document Type: Article

References (46)

1. Ahmed, S., A. Rahman, A. Hasnain, M. Lalonde, V.M. Goldberg and T.M. Haqqi, 2002. Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1 beta-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radic. Biol. Med., 33: 1097-1105.
2. Amin, A.R. and S.B. Abramson, 1998. The role of nitric oxide in articular cartilage breakdown in osteoarthritis. Curr. Opin. Rheumatol., 10: 263-268.
3. 2. Exp. Cell Res., 218: 319-325.
4. Bollet, A.J., 1968. Stimulation of protein-chondroitin sulfate synthesis by normal and osteoarthritic articular cartilage. Arthr. Rheum., 11: 663-673.
5. Cawston, T.E., A.J. Ellis, H. Bigg, V. Curry, E. Lean and D. Ward, 1996. Interleukin-4 blocks the release of collagen fragments from bovine nasal cartilage treated with cytokines. Biochim. Biophys. Acta, 1314: 226-232.
6. Cawston, T., 1998. Matrix metalloproteinases and TIMPs: Properties and implications for the rheumatic diseases. Mol. Med. Today, 4: 130-137.
7. Celeste, C., M. Ionescu, A. Robin Poole and S. Laverty, 2005. Repeated intraarticular injections of triamcinolone acetonide alter cartilage matrix metabolism measured by biomarkers in synovial fluid. J. Orthop. Res., 23: 602-610.
8. Chou, M.M., N. Vergnolle, J.J. Mcdougall, J.L. Wallace, S. Marty, V. Teskey and A.G. Buret, 2005. Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1β, matrix metalloprotease-9 and cartilage damage in Arthr. Exp. Biol. Med. (Maywood), 230: 255-262.
9. Cipolletta, C., J.Y. Jouzeau, P. Gegout-Pottie, N. Presle, K. Bordji, P. Netter and B. Terlain, 1998. Modulation of IL-1-induced cartilage injury by NO synthase inhibitors: A comparative study with rat chondrocytes and cartilage entities. Br. J. Pharmacol., 124: 1719-1727.
10. Dean, D.D., J. Martel-Pelletier, J.P. Pelletier, D.S. Howell and J.F. Woessner, Jr., 1989. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J. Clin. Invest., 84: 678-685.
11. Fenton, J.I., K.A. Chlebek-Brown, J.P. Caron and M.W. Orth, 2002. Effect of glucosamine on interleukin-1-conditioned articular cartilage. Equine Vet. J. Suppl., pp: 219-223.
12. Garbacki, N., L. Angenot, C. Bassleer, J. Damas and M. Tits, 2002. Effects of prodelphinidins isolated from Ribes nigrum on chondrocyte metabolism and COX activity. Naunyn Schmiedebergs Arch. Pharmacol., 365: 434-441.
13. Goggs, R., S.D. Carter, G. Schulze-Tanzil, M. Shakibaei and A. Mobasheri, 2003. Apoptosis and the loss of chondrocyte survival signals contribute to articular cartilage degradation in osteoarthritis. Vet. J., 166: 140-158.
14. Goldring, M.B., J.R. Birkhead, L.F. Suen, R. Yamin, S. Mizuno, J. Glowacki, J.L. Arbiser and J.F. Apperley, 1994. Interleukin-1 beta-modulated gene expression in immortalized human chondrocytes. J. Clin. Invest., 94: 2307-2316.
15. Hanson, R.R., W.R. Brawner, M.A. Blaik, T.A. Hammad, S.A. Kincaid and D.G. Pugh, 2001. Oral treatment with a nutraceutical (Cosequin®) for ameliorating signs of navicular syndrome in horses. Vet. Therap., 2: 148-159.
16. Hardy, M.M., K. Seibert, P.T. Manning, M.G. Currie, B.M. Woerner, D. Edwards, A. Koki and C.S. Tripp, 2002. Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthr. Rheum., 46: 1789-1803.
17. Hasegawa, T., 2004. Suppressive effect of methylsulfonylmethane (MSM) on type II collagen-induced arthritis in DBA/1J mice. Jap. Pharmacol. Ther., 32: 421-427.
18. Hoffman, A.R., 2001. Treatment with Cosequin® of bilateral coxofemoral osteoarthritis in a Great Dane. Compen. Contin. Educ. Pract. Vet., 23: 888-894.
19. Hunter, T., 2000. Signaling-2000 and beyond. Cell, 100: 113-127.
20. Johnson, K.A., D.A. Hulse, R.C. Hart, D. Kochevar and Q. Chu, 2001. Effects of an orally administered mixture of chondroitin sulfate, glucosamine hydrochloride and manganese ascorbate on synovial fluid chondroitin sulfate 3B3 and 7D4 epitope in a canine cruciate ligament transection model of osteoarthritis. Osteoarth. Cartil., 9: 14-21.
21. Johnston, S.A., 1997. Osteoarthritis. Joint anatomy, physiology and pathobiology. Vet. Clin. North Am. Small Anim. Pract., 27: 699-723.
22. Kuroki, K., J.L. Cook and J.M. Kreeger, 2002. Mechanisms of action and potential uses of hyaluronan in dogs with osteoarthritis. J. Am. Vet. Med. Assoc., 221: 944-950.
23. Langman, M.J., D.M. Jensen, D.J. Watson, SE. Harper, P.L. Zhao, H. Quan, J.A. Bolognese and T.J. Simon, 1999. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA., 282: 1929-1933.
24. Lees, P., 2003. Pharmacology of drugs used to treat osteoarthritis in veterinary practice. Inflammopharm, 11: 385-399.
25. Lubke, C., M. Sittinger, G.R. Burmester and M. Paulitschke, 2001. Cryopreservation of artificial cartilage: Viability and functional examination after thawing. Cells Tissues Organs, 169: 368-376.
26. Manfield, L., D. Jang and G.A. Murrell, 1996. Nitric oxide enhances cyclooxygenase activity in articular cartilage. Inflamm. Res., 45: 254-258.
27. Mani, S. and J.W. Lawson, 2006. In vitro modulation of inflammatory cytokine and IgG levels by extracts of Perna canaliculus. BMC Complement. Alter. Med., 6: 1.
28. Mbvundula, E.C., R.A. Bunning and K.D. Rainsford, 2005. Effects of cannabinoids on nitric oxide production by chondrocytes and proteoglycan degradation in cartilage. Biochem. Pharmacol., 69: 635-640.
29. Moncada, S., R.M. Palmer and E.A. Higgs, 1991. Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol. Rev., 43: 109-142.
30. Morris, E.A., B.S. Mcdonald, A.C. Webb and L.J. Rosenwasser, 1990. Identification of interleukin-1 in equine osteoarthritic joint effusions. Am. J. Vet. Res., 51: 59-64.
31. Moulton, P.J., 1996. Inflammatory joint disease: The role of cytokines, cyclooxygenases and reactive oxygen species. Br. J. Biomed. Sci., 53: 317-324.
32. Nadaud, S. and F. Soubrier, 1995. Biologie moleculaire et genetique des NO-synthetases. C. R. Soc. Biol., 189: 1025-1038.
33. O'brien, J., I. Wilson, T. Orton and F. Pognan, 2000. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur. J. Biochem., 267: 5421-5426.
34. Panico, A.M., V. Cardile, F. Garufi, C. Puglia, F. Bonina and G. Ronsisvalle, 2005. Protective effect of Capparis spinosa on chondrocytes. Life Sci., 77: 2479-2488.
35. Pollard, B., W.G. Guilford, K.L. Ankenbauer-Perkins and D. Hedderley, 2006. Clinical efficacy and tolerance of an extract of green-lipped mussel (Perna canaliculus) in dogs presumptively diagnosed with degenerative joint disease. N. Z. Vet. J., 54: 114-118.
36. Remsberg, C.M., J.A. Yanez, Y. Ohgami, K.R. Vega-Villa, A.M. Rimando and N.M. Davies, 2007. Pharmacometrics of pterostilbene: Preclinical pharmacokinetics and metabolism, anticancer. Antiinflammatory, antioxidant and analgesic activity. Phytother. Res. (In Press).
37. Serena, A., J. Schumacher, M.C. Schramme, F. Degraves, E. Bell and W. Ravis, 2005. Concentration of methylprednisolone in the centrodistal joint after administration of methylprednisolone acetate in the tarsometatarsal joint. Equine Vet. J., 37: 172-174.
38. Stadler, J., M. Stefanovic-Racic, T.R. Billiar, R.D. Curran, L.A. Mcintyre, H.I. Georgescu, R.L. Simmons and C.H. Evans, 1991. Articular chondrocytes synthesize nitric oxide in response to cytokines and lipopolysaccharide. J. Immunol., 147: 3915-3920.
39. Tetlow, L.C., D.J. Adlam and D.E. Woolley, 2001. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: Associations with degenerative changes. Arthr. Rheum., 44: 585-594.
40. Van De Loo, A.A. and W.B. Van Den Berg, 1990. Effects of murine recombinant interleukin 1 on synovial joints in mice: Measurement of patellar cartilage metabolism and joint inflammation. Ann. Rheum. Dis., 49: 238-245.
41. Van De Loo, F.A., L.A. Joosten, P.L. Van Lent, O.J. Arntz and W.B. Van Den Berg, 1995. Role of interleukin-1, tumor necrosis factor alpha and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthr. Rheum., 38: 164-172.
42. Van Der Kraan, P.M. and W.B. Van Den Berg, 2000. Anabolic and destructive mediators in osteoarthritis. Curr. Opin. Clin. Nutr. Metab. Care, 3: 205-211.
43. Vetri-Science, 2006a. Glyco-Flex (glyco flex) III and Soft Chew, glycoflex for dogs. Joint Support.
44. Vetri-Science, 2006b. Glyco-Flex Client Brochure
45. Walker, J.S., R.B. Sheather-Reid, J.J. Carmody, J.H. Vial and R.O. Day, 1997. Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis: Support for the concept of responders and nonresponders. Arthr. Rheum., 40: 1944-1954.
46. Wolfe, M.M., D.R. Lichtenstein and G. Singh, 1999. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N. Eng. J. Med., 340: 1888-1899.